Scarica l'app Stockscreener
150.93
0.42%
-0.63
Pre-mercato:
151.24
0.31
+0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$151.56
Aprire:
$150.46
Volume 24 ore:
1.58M
Relative Volume:
1.00
Capitalizzazione di mercato:
$287.99B
Reddito:
$54.66B
Utile/perdita netta:
$13.58B
Rapporto P/E:
21.51
EPS:
7.0171
Flusso di cassa netto:
$16.05B
1 W Prestazione:
+1.21%
1M Prestazione:
+1.92%
6M Prestazione:
+11.78%
1 anno Prestazione:
+27.81%
Intervallo 1D:
$148.64
$151.38
Intervallo di 1 settimana:
$147.91
$154.71
Portata 52W:
$112.34
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.93 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,122.50 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.18 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
222.47 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.17 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Argus | Hold → Buy |
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2026-01-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) - GlobeNewswire Inc.
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
NVS Stock Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis stock (CH0012005267): FDA progress and market focus - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): dividend profile and pipeline focus move into the spotlight - AD HOC NEWS
Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG stock (CH0012005267): Recent 1.93% gain on SIX Swiss Exchange - AD HOC NEWS
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report - Sahm
Sandoz, Novartis Must Face Generics Claims From GM, Others - Law360
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):